HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $3.11 million. The enterprise value is $8.82 million.
Important Dates
The next estimated earnings date is Friday, March 27, 2026, after market close.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 5.76 million shares outstanding. The number of shares has increased by 62.33% in one year.
| Current Share Class | 5.76M |
| Shares Outstanding | 5.76M |
| Shares Change (YoY) | +62.33% |
| Shares Change (QoQ) | +26.96% |
| Owned by Insiders (%) | 11.01% |
| Owned by Institutions (%) | 2.55% |
| Float | 5.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.37 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.66% |
| Return on Invested Capital (ROIC) | -214.94% |
| Return on Capital Employed (ROCE) | 931.06% |
| Weighted Average Cost of Capital (WACC) | 9.50% |
| Revenue Per Employee | $11,723 |
| Profits Per Employee | -$616,834 |
| Employee Count | 36 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.30% in the last 52 weeks. The beta is 0.72, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -96.30% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 22.94 |
| Average Volume (20 Days) | 141,506 |
Short Selling Information
The latest short interest is 53,964, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 53,964 |
| Short Previous Month | 21,438 |
| Short % of Shares Out | 0.94% |
| Short % of Float | 1.05% |
| Short Ratio (days to cover) | 0.54 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $422,026 and -$22.21 million in losses. Loss per share was -$14.70.
| Revenue | 422,026 |
| Gross Profit | 84,406 |
| Operating Income | -13.17M |
| Pretax Income | -12.05M |
| Net Income | -22.21M |
| EBITDA | -11.60M |
| EBIT | -13.17M |
| Loss Per Share | -$14.70 |
Full Income StatementBalance Sheet
The company has $1.10 million in cash and $6.81 million in debt, with a net cash position of -$5.71 million or -$0.99 per share.
| Cash & Cash Equivalents | 1.10M |
| Total Debt | 6.81M |
| Net Cash | -5.71M |
| Net Cash Per Share | -$0.99 |
| Equity (Book Value) | -2.11M |
| Book Value Per Share | -0.80 |
| Working Capital | -25.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.87 million and capital expenditures -$113,412, giving a free cash flow of -$12.98 million.
| Operating Cash Flow | -12.87M |
| Capital Expenditures | -113,412 |
| Free Cash Flow | -12.98M |
| FCF Per Share | -$2.26 |
Full Cash Flow StatementMargins
| Gross Margin | 20.00% |
| Operating Margin | -3,120.97% |
| Pretax Margin | -2,855.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.33% |
| Shareholder Yield | -62.33% |
| Earnings Yield | -713.49% |
| FCF Yield | -417.20% |
Analyst Forecast
The average price target for HCW Biologics is $35.00, which is 6,374.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 6,374.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 151.03% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
HCW Biologics has an Altman Z-Score of -8.6 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.6 |
| Piotroski F-Score | 1 |
